ST. LOUIS, /PRNewswire/ — Isto Biologics is wasting no time in showcasing its bone-regeneration technologies and cell-based therapy to industry leaders and spine surgeons. Isto Biologics, resulting from the combination of Isto Technologies and Arteriocyte Medical Systems, will participate in the 2016 North American Spine Society (NASS) annual meeting in .
“The combination of Isto Technologies and Arteriocyte Medical Systems expands our best-in-class product portfolios and builds upon our collective, deep scientific expertise in biologics and cell therapy to provide better patient outcomes,” said , Isto’s chief commercial officer. “I cannot think of a better place than the NASS meeting for our public debut.”
Orthopedic surgeon , M.D., will give a presentation during the meeting’s Innovative Technologies Sessions highlighting his noteworthy research using concentrated bone marrow aspirate. Dr. Stazzone will share his research comparing marrow-derived progenitor cells from pediatric patients and adults.
We are looking forward to hearing Dr. Stazzone’s research presentation on marrow-derived progenitor cells and his experience using our CellPoint concentrated bone marrow aspirate system. We’re excited that he, along with other experts from our scientific and clinical team, will be on site to answer specific questions about our cutting-edge biologics,” stated , director of marketing. “NASS provides us the perfect opportunity to share our company announcement and provide more information about our combined product portfolio with leading spine surgeons.”
NASS’s annual meeting is the ideal setting to share the latest information, innovative techniques and best practices with renowned spine care professionals from around the world. The meeting delivers dynamic and challenging educational programs, outstanding exhibitions and the chance to network and build relationships with celebrated spine professionals. NASS 2016 is being held Oct. 26–29 in Boston at the Boston Convention and Exhibition Center.
About Isto Biologics
Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, combined under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company’s best-in-class product offerings include Arteriocyte’s market-leading MAGELLAN® Autologous Platelet Separator System and Isto’s bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.
For more information, visit www.istobiologics.com
Director of Marketing
SOURCE Isto Biologics